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Purpose: Antagonists of α1-adrenergic receptors (α1ARs) relax prostate smooth muscle and relieve voiding and storage symp-
toms. Recently, increased expression of α1ARs with change of its subtype expression has been proved in bladder outlet obstruc-
tion (BOO). To search for the evidence of changes in α1ARs subtype expression and activity in the peripheral and spinal routes, 
the effects of spinal and peripheral administration of tamsulosin (an α1A/D-selective AR), naftopidil (an α1A/D-selective AR), 
and doxazosin (non-selective AR) on bladder activity were investigated in a rat model with or without BOO. 
Methods: A total of 65 female Sprague-Dawley rats were divided into the BOO surgery group (n=47) and the sham surgery 
group (n=18). After 6 weeks, cystometry was assessed before and after intrathecal and intra-arterial administrations of tamsu-
losin, naftopidil, and doxazosin. 
Results: After intra-arterial administrations of all three drugs, bladder capacity (BC) was increased and maximal intravesical 
pressure (Pmax) was decreased in both BOO and the sham rat models (P<0.05). After intrathecal administration of all three 
drugs, BC was increased and Pmax was decreased in only the BOO group. The episodes of involuntary contraction in the BOO 
rat models were decreased by intra-arterial administration (P=0.031). The increase of BC after intrathercal and intra-arterial 
administrations of α1ARs was significantly greater in the BOO group than in the sham group (P=0.023, P=0.041). In the BOO 
group, the increase of BC and decrease in Pmax were greater by intra-arterial administration than by intrathecal administration 
(P=0.035). There were no significant differences of the degrees of changes in the cystometric parameters among the three differ-
ent α1ARs.
Conclusions: Up-regulations of the α1ARs in BOO were observed by the greater increases of BC after α1AR antagonist admin-
istrations in the BOO group than in the sham group. However, there were no subtype differences of the α1ARs in functional pa-
rameters of bladder activity. In addition, α1ARs also act on the lumbosacral cord which implies that the sensitivity of α1ARs is 
increased in pathologic models such as BOO. Further evaluation including differential expression of α1ARs in BOO models are 
need.
Keywords: Urinary bladder; Urinary bladder neck obstruction; Adrenergic alpha-antagonists; Rats
Corresponding author:  Jae Hyun Bae
Department of Urology, Korea University Ansan Hospital, Korea University 
College of Medicine, 516 Gojan-dong, Danwon-gu, Ansan 425-707, Korea
Tel: +82-31-412-5190 / Fax: +82-31-412-5194 
E-mail: urobae@genetherapy.or.kr
Submitted:  December 1, 2011 / Accepted after revision:  December 23, 2011
INTRODUCTION
Bladder outlet obstruction (BOO) is a common disease among 
aged males, that usually caused by benign prostate hyperplasia 
(BPH), and leads to voiding and storage dysfunction. In partic-
ular, storage symptoms such as frequency, nocturia, and urgen-
cy are bothersome problems and have a significant impact on 
quality of life [1].
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Currently α1 adrenergic receptor (α1AR) antagonists are con-
sidered the first-line drug treatment for BPH. Alpha-1ARs are 
generally subdivided into α1A, α1B, and α1D AR subtypes [2]. 
Highly selective α1ARs are effective for the treatment of BOO, 
but they do not appear to relieve storage symptoms. Because 
non-subtype-selective α1AR antagonists have been shown to 
relieve voiding and storage symptoms, it is logical to conclude 
that another distinct (non α1A) subtype mediates storage re-
sponses. A number of experimental studies have shown the ex-
pression of the α1D AR subtype in the detrusor, urothelium, 
prostate, peripheral ganglia and spinal cord in humans and rats 
[3,4], which suggests the involvement of the α1D AR subtype in 
storage dysfunction and related storage symptoms [5]. It has also 
been reported that the α1D AR in the bladder trigone, body, and 
dome markedly increase, and weight and overactivity also in-
crease, after incomplete urethral obstruction produced for 6 
weeks in female rats [6].
  Tamsulosin and naftopidil are well-known α1A/D-selective 
ARs, but their receptor selectivity is quite different that their af-
finity to α1A or α1D AR is dissimilar [7]. Most of experimental 
studies of BOO models have focused on tamsulosin and other 
non-selective ARs, and experiments using naftopidil in BOO 
models are scarce.
  One of the important motives of this study was to investigate 
the evidence for changes in α1AR subtype expression and activ-
ity in the peripheral and spinal routes. We investigated the ef-
fects of spinal and peripheral administraion of tamsulosin (an 
α1A/D-selective AR), naftopidil (an α1A/D-selective AR), and 
doxazosin (non-selective AR) on bladder activity in a rat model 
with or without BOO. 
MATERIALS AND METHODS
Experimental Design
At 12 to 14 weeks of age, female Sprague-Dawley rats weighing 
180 to 210 g at acquisition underwent partial BOO (BOO rats; 
n=47) or sham surgery (sham group; n=18). After 6 weeks, a 
polyethylene tube was inserted for cystometry, and an intrathe-
cal catheter and intra-arterial catheter were inserted at the same 
time. Cystometry was assessed before and after intrathecal and 
intra-arterial administration of α1ARs antagonists (tamsulosin, 
naftopidil, and doxazosin) (Fig. 1). Drug administration was 
done in the middle of the micturition cycle after establishing a 
constant contractile activity. The effects of drugs on the cysto-
metric parameters were monitored more than 60 minutes.
Creation of BOO
Female Sprague-Dawley rats were anesthetized with intraperi-
toneal ketamine (80 mg/kg; Ketamine, Yuhan, Seoul, Korea) 
and xylazine (10 mg/kg; Rompun,, Bayer Korea Ltd., Seoul, Ko-
rea). Surgical creation was performed by using sterile techniques. 
Through an abdominal incision, the bladder neck and the ure-
thra were introduced without damaging the bladder. A 3-0 silk 
suture was placed around the urethra with a polyethylene tube 
(outside diameter: 1.09 mm) placed on the ventral side of the 
urethra. Subsequently, the urethra and tube were ligated loosely 
to avoid urethral compression and the tube was removed with a 
securing suture. The bladder was returned to the normal posi-
tion in the abdomen, and the incision was closed.
  Sham surgeries were performed in identical fashion in 18 
rats except for the urethral ligatures. After these steps, the blad-
der was returned to its normal position in the abdomen, and 
the incision was closed.
Intrathecal Catheter Implantation
Intrathecal catheters were implanted at the same time as the 
bladder catheters for cystometry after anesthesia with intraperi-
toneal ketamine and xylazine. A polyethylene catheter (PE-10) 
was inserted into the subarachnoid space at the level of the L6-
S1 spinal cord segments for intrathecal administration of drugs 
as described previously [8]. The injection sites in the spinal cord 
and the extent of dye distribution were confirmed by injection 
of dye (1% methylene blue) in every animal at the end of the 
procedure.
Intra-Arterial Catheter Implantation
The femoral artery was exposed through an inguinal incision, 
and a PE-10 tube filled with heparinized saline (30 IU/mL) was 
inserted and advanced proximally to the abdominal aortic bi-
Cystometry before drug administration
Cystometry after drug administration (Intrathecal and intra-arterial injection)
Tamsulosin
(n=16)
Naftopidil
(n=16)
Doxazosin
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Fig. 1. Experimental design.www.einj.or.kr    201
  Kim, et al.  •  Effects of Spinal or Peripheral α1 Adrenoceptor Antagonism
http://dx.doi.org/10.5213/inj.2011.15.4.199
INJ
furcation. The catheter was tunneled subcutaneously and an 
orifice was made on the ventral skin of the rat.
Functional Evaluation of Cystometry 
The abdomen was opened through a midline incision, and a 
PE-160 polyethylene tube with double lumen catheter was in-
serted into the bladder dome. A PE-150 tube was implanted 
into the bladder through the dome and connected to both a 
micro-injection pump (Harvard infusion pump) for continu-
ous saline infusion and a polygraph (0.25 mm/sec) to monitor 
changes in intravesical pressure via a pressure transducer (P-
23XL, Gilson Inc., Middleton, WI, USA). Saline (normal tem-
perature) was infused into the bladder at a constant rate of 0.1 
mL/min to induce a micturition reflex. After an equilibration 
period, three reproducible micturition cycles were recorded be-
fore drug administration and were used as baseline values. Af-
ter a stabilization period of at least 30 minutes, cystometric re-
cording was used to evaluate the cystometric parameters.
  The cystometric parameters analyzed were bladder capacity 
(BC), maximal bladder pressure, and involuntary contraction. 
Bladder capacity was defined as the highest capacity until the 
initiation of the micturition reflex. Maximal vesical pressure 
(Pmax) was defined as the highest pressure from baseline blad-
der pressure. Involuntary contraction was defined as as sponta-
neous detrusor contractions with an amplitude of 4 cm water 
or more that were not associated with during the bladder filling 
state [9]. Involuntary contraction was observed in 44 rats among 
BOO group and in one rat in sham group.
  The three micturition cycles showing the most pronounced 
changes (increase or decrease) after administration of the drugs 
were analyzed and compared with the baseline values.
Drugs and Administration 
Doxazosin (Pfizer Central Research, Sandwich, UK), tamsulo-
sin (Astellas Pharm Inc., Ibaraki, Japan), and naftopidil (Asahi 
Kasei Co., Tokyo, Japan) were used. After establishing constant 
bladder contractile activity and accompanying micturition dur-
ing the equilibration period, drugs were administered in the 
middle of the micturition cycle. Stock solutions of all drugs were 
made in distilled water. All drugs were administered carefully at 
an interval of 30 seconds to minimize volume effects. To assess 
the effects of solvents, normal saline was administered before 
drug administration. Drugs were administered intrathecally 
through the spinal catheter in a volume of 20 μL for 20 seconds 
and intra-arterially in a volume of 0.2 mL/100 g. All drugs were 
delivered by intrathecally and intra-arterially with the concen-
tration of 1.0 μmol/L [10].
Statistical Analysis
Parametric tests were conducted because the data were shown 
to be normally distributed. The results are given as mean values 
±standard errors. For comparisons between values obtained 
before and after drug administration, Student’s paired t-tests 
were used. One-way analysis of variance was used for compari-
sons among the drugs. SPSS ver. 18.0 (IBM, New York, NY, USA) 
was used for statistical processing and differences were consid-
ered to be significant when P<0.05.
RESULTS
Bladder Weight 
The mean bladder weight of the rats that underwent BOO sur-
gery was significantly greater than that of the sham rats (Fig. 2). 
An approximately 1.7 to 2.8-fold increase in bladder weight was 
observed. There were no significant differences in bladder weight 
among the drug administration group both in BOO and sham 
group. 
Effects of Intrathecal and Intra-Arterial Administration of 
α1AR Antagonists on Bladder Activity in the Sham Surgery 
Group
After intra-arterial administration of all types of α1ARs antago-
Fig. 2. Box-plot of mean bladder weight. The bladder weight of 
the bladder outlet obstruction (BOO) group was significantly 
greater than that of the sham group (P<0.05). There were no 
significant differences among the drug administration subgroups 
in the BOO or sham group (P>0.05).
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nists, BC was increased and maximal Pmax was decreased with 
statistical difference (P=0.031, P=0.022). After intrathecal ad-
ministration of all types of α1AR antagonists, BC and Pmax 
showed no siginificant difference compared with baseline val-
ues (Table 1). 
Effects of Intrathecal and Intra-Arterial Administration of 
α1ARs Antagonists on Bladder Activity in the BOO Group
After intra-arterial administration of all types of α1AR antago-
nists, BC was increased and Pmax was decreased with statistical 
difference (P=0.021, P=0.012). After intrathecal administra-
tion of all types of α1ARs antagonists, BC was increased and 
Pmax was decreased with statistical difference (P=0.041, P= 
0.015). The episodes of involuntary contraction in the BOO rat 
models were decreased by intra-arterial administration (P= 
0.031; Table 1).
Comparison of Bladder Activity after Intrathecal and after 
Intra-Arterial Administration of α1AR Antagonists
In the BOO group, the increase of BC and decrease of Pmax 
were greater with intra-arterial administration than with intra-
thecal administration (P=0.035, P=0.025). In the sham group 
there were no significant differences between intrathecal and 
intra-arterial administration (Table 2). 
Comparison of Bladder Activity after Intrathecal and Intra-
Arterial Administration of α1ARs Antagonists between the 
Sham and BOO Groups
Differentials of BC (Δ BC) before and after administration of 
α1ARs antagonists showed a greater increase in the BOO group 
than in the sham group (P=0.041, P=0.023). Differentials of 
maximal intravesical pressure (Δ Pmax) before and after ad-
ministrations of α1AR antagonists showed no differences in the 
BOO group compared with sham group (P>0.05; Table 3). 
Comparison of Bladder Activity after Intrathecal and Intra-
Arterial Administration of α1ARs among Tamsulosin, 
Naftopidil, and Doxazosin 
Differentials of Δ BC, Δ Pmax, and Δ involuntary contractions 
showed no significant differences among the tamsulosin, naf-
topidil, and doxazosin administration groups in the BOO group 
(Table 4). Differentials of Δ BC, Δ Pmax, Δ involuntary con-
tractions also did not differ significantly among tamsulosin, 
naftopidil, and doxazosin administration groups in the sham 
group.
Table 1. Changes in functional parameters before and after administration of α-adrenoceptor antagonists in rats
Variable Group Route Before administration After administration P-value
a)
BC (mL) BOO Intra-arterial 0.91±0.56 1.09±0.67 0.021
Intrathecal 0.38±0.15 0.41±0.22 0.041
Sham group Intra-arterial 1.04±0.98 1.51±1.81 0.031
Intrathecal 0.66±0.30 0.85±0.41 >0.05
Pmax (mmHg) BOO Intra-arterial 22.75±12.26 19.64±11.88 0.012
Intrathecal 20.42±6.70 18.04±6.15 0.015
Sham group Intra-arterial 20.00±17.06 16.44±14.50 0.022
Intrathecal 16.93±13.09 14.41±13.01 >0.05
Involuntary contraction (time/min) BOO Intra-arterial 0.68±1.19 0.50±0.89 0.031
Intrathecal 0.35±0.41 0.32±0.40 >0.05
Values are presented as mean±standard deviation.
BC, bladder capacity; Pmax, maximal intravesical pressure; BOO, bladder outlet obstruction.
a)Statistically analyzed by paired t-test. 
Table 2. Comparison of bladder activity after intrathecal and af-
ter intra-arterial administration of α1ARs antagonists
Intrathecal ad-
ministration
Intra-arterial 
administration P-value
a)
Δ BC (mL) BOO 0.19±0.16 0.46±0.92 0.035
Sham group 0.04±0.09 0.18±0.22 >0.05
Δ Pmax 
(mmHg)
BOO 2.52±2.41 3.55±3.50 0.025
Sham group 2.38±2.08 3.11±2.15 >0.05
Values are presented as mean±standard deviation. 
Δ BC, differentials of bladder capacity; Δ Pmax, differentials maximal 
intravesical pressure; BOO, bladder outlet obstruction. 
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DISCUSSION 
Many reports have stated that α-blockers have pharmacologic 
and clinical effects in the treatment of voiding and storage 
symptoms in BPH; however the pathogenic mechanism and 
treatment of storage symptoms are not clearly understood. It is 
clear that the most reasonable explanation for the limited role 
of α-blockers is the up-regulation of the α1ARs, with changes in 
their subtypes, and α1AR-mediated bladder afferent activation 
[11]. In our study, we tried to investigate on the up-regulation 
of α1ARs and its subtype change, and spinal and peripheral 
α1AR antagonism on bladder activity. 
  The composition of human α1ARs measured quantitatively 
by mRNA is follows: α1A, 6 to 74%; α1B, 1 to 6%; and α1D, 25 
to 31% [12]. Weinberg et al. [13] reported similar results. Mal-
loy et al. [3], however, investigated the expression of α1receptor 
mRNA in the human bladder detrusor muscle, and revealed 
the distribution of subtypes of α1 receptors to be 34% α1A, and 
66% α1D. Hampel et al. [14] showed that there was a change in 
α1AR subtype expression from α1A to α1D AR in detrusor 
muscle in rats with BOO. However, it remains to be elucidated 
whether α1ARs (mainly α1D) in the detrusor muscle are re-
sponsible for detrusor overactivity [15]. A shift from α1A AR to 
α1D AR and de novo α1D AR protein expression is predomi-
nant in BOO rat models, particularly in bladders with a mass 
more than 5-fold the mean of sham bladder masses [14].
  Although the changes in AR subtypes are important, α1AR-
mediated bladder afferent activation is another important 
mechanism for understanding overactivity in BOO experimen-
tal models. Recently, it was reported that α1AR antogonists are 
effective in the treatment of storage symptoms [16]. This sug-
gests that not only the α1D AR but also the α1A AR may have 
an important role in the development of storage symptoms. With 
regard to the mechanisms of α1AR antagonists in the improve-
ment of storage symptoms, recent attention has focused on the 
possibility that α1AR antagonists may inhibit afferent nerves 
from the lower urinary tract [16].
  With regard to α1AR-mediated bladder afferent activation, 
the expression of α1ARs in the urothelium has been well docu-
mented. Up-regulation of these receptors can trigger the release 
of a number of mediators including ATP and nitric oxide, which 
may modulate bladder afferent nerve activity [17]. Alpha 1 ARs 
located in the bladder urothelium, primary sensory nerve, and 
bladder vessel, are involved in afferent signaling. It is suggested 
that α1AR antagonists may decrease bladder afferent activity by 
blocking α1ARs in these sites, thereby reducing the storage dys-
function associated with BOO [18].
  In our study, intra-arterial administration of α1AR antago-
nists showed that BC was increased and Pmax was decreased in 
both BOO and sham group. But after intrathecal administra-
tion of α1AR antagonists, BC was increased and Pmax was de-
creased in only BOO group. Involuntary contraction was de-
creased only after intra-arterial administration of α1AR antago-
nists in the BOO group. These results may reflect the inhibition 
of the micturition reflex not only at a spinal but also at the pe-
ripheral level, and in pathologic models spinal receptor sensi-
tivity is more increased than in normal models [10].
  The most prominent feature of our study is that we directly 
compared the bladder activity among tamsulosin, naftopidil 
Table 3. Comparison of BC and Pmax between the BOO and 
sham groups
Sham group BOO P-value
a)
Δ BC (mL)
Intra-arterial 0.18±0.22 0.46±0.92 0.041
Intrathecal 0.04±0.09 0.19±0.16 0.023
Δ Pmax (mmHg)
Intra-arterial 3.11±2.15 3.55±3.50 >0.05
Intrathecal 2.38±2.08 2.52±2.41 >0.05
Values are presented as mean±standard deviation. 
Δ BC, differentials of BC bladder capacity; Δ Pmax, differentials of 
maximal intravesical pressure; BOO, bladder outlet obstruction. 
a)Statistically analyzed by paired t-test.
Table 4. Comparison of the parameters among the drug treat-
ment goups in BOO rats
Tamsulosin Naftopidil Doxazosin P-value
a)
Δ BC (mL)
Intra-arterial 0.70±1.48 0.40±0.47 0.26±0.23 >0.05
Intrathecal 0.15±1.09 0.20±0.23 0.22±0.04 >0.05
Δ Pmax (mmHg)
Intra-arterial 5.19±3.35 1.85±1.44 4.64±5.29 >0.05
Intrathecal 2.11±1.77 3.35±3.28 2.16±2.11 >0.05
Δ Involuntary contraction (time/min)
Intra-arterial 0.09±0.23 0.37±0.69 0.08±0.17 >0.05
Intrathecal 0.03±0.08 0.04±0.15 0.02±0.15 >0.05
Values are presented as mean±standard deviation. 
Δ BC, differentials of bladder capacity; Δ Pmax, differentials of maxi-
mal intravesical pressure; BOO, bladder outlet obstruction.
a)Statistically analyzed by one-way analysis of variance. 204    www.einj.or.kr
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and doxazosin treatment groups. Before the emergence of naf-
topidil, there was no α1A/D-selective AR, and most studies 
have used tamsulosin. Naftopidil and tamsulosin are α1 block-
ers of the same category in that they have antagonistic action on 
both α 1A and α1D receptors, but they have an affinity contrary 
to each other [7]. Naftopidil has an affinity to α1D AR about 3.1 
times as high as the affinity to α1A AR. The affinity of tamsulo-
sin, which is commonly used as an α1 blocker, has an affinity to 
α1A AR about 3.3 times as high as the affinity to α1D AR [7].
  In our study, the increase of BC after intrathercal and intra-
arterial administrations of α1ARs was significantly greater in 
the BOO than in sham rat models but there were no significant 
differences in the degrees of the changes in the cystometric pa-
rameters among the three different α1ARs antagonists. To our 
knowledge, there have been no experimental reports compar-
ing bladder activity among tamsulosin, naftopidil and doxazo-
sin treatment groups. 
  Although our method is not direct, such as detecting recep-
tor expression for evidence of the up-regulation of α1ARs and 
changes in subtype expression, our experiment has yield a defi-
nite results on functional study by intrathecal and intra-arterial 
administration of each α1ARs. The most ideal method of de-
tecting the up-regulation of α1ARs and changes in subtype ex-
pression is to use the robust method of quantitative competitive 
reverse transcriptase-polymerase chain reaction [19]. However, 
the localization of bladder α1ARs is not a simple method be-
cause of low sensitivity [20].
  Our study had some limitations. First, cystometry was not 
performed with the rats in a conscious state and voiding behav-
ior was not investigated before and after BOO surgery. It is bet-
ter to perform the experiments without than with anesthesia 
because it has been reported that anesthesia affects urinary 
function [21]. Although we did not collect voiding behavior 
data, analysis of bladder weights indicated that our surgical 
procedure for the BOO model resulted in changes approximat-
ing detrusor hypertrophy in clinical BOO. Second, spinal and 
peripheral bolus injections of α1AR antagonists are not a natu-
ral treatment model. Third, drug uroselectivity is different in 
rats than in other species (rabbits, dogs and humans) [22, 23].
  In conclusion, our study implies that both central and pe-
ripheral effects of a and a1-adrenoceptor antagonists may con-
tribute to the increase BC and the decrease in the Pmax after 
intrathecal and intra-arterial administration, but the exact role 
of detrusor α1ARs in the bladder overactivity after BOO re-
mains to be completely elucidated. The present study demon-
strates that tamsulosin, naftopidil, and doxazosin increase BC 
and decrease maximal bladder pressure in BOO models. Future 
study must be performed examining the definite role of α1ARs 
and their subtypes and α1AR-mediated bladder afferent activa-
tion to elucidate the pathologic mechanism of storage symp-
toms in BOO.
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